Filtered By:
Source: Thrombosis and Haemostasis
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 186 results found since Jan 2013.

Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
This report is based on findings from the Anticoagulation Education Task Force, which brought together patient groups and professionals representing different medical specialties with an interest in patient safety and expertise in AF, VTE, stroke, anticoagulation, and reversal agents, to discuss the current status of anticoagulation reversal and fundamental changes in management of bleeding associated with DOACs occasioned by the approval of idarucizumab, a specific reversal agent for dabigatran, as well as recent clinical data on specific reversal agents for factor Xa inhibitors. Recommendations are given for when there i...
Source: Thrombosis and Haemostasis - August 3, 2016 Category: Hematology Authors: Ageno W, Büller HR, Falanga A, Hacke W, Hendriks J, Lobban T, Merino J, Milojevic IS, Moya F, van der Worp HB, Randall G, Tsioufis K, Verhamme P, Camm AJ Tags: Thromb Haemost Source Type: research

Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Abstract All pivotal trials have evaluated non-vitamin K oral antagonists (NOACs) against warfarin. However, in some regions of the world, phenprocoumon is the most widely used vitamin K antagonist (VKA). There is little evidence documenting effectiveness and safety of NOACs compared with phenprocoumon in atrial fibrillation (AF). A retrospective cohort study using a German claims database was conducted to assess effectiveness (stroke, systemic embolism [SE]) and safety (bleeding leading to hospitalization) during therapy with NOACs and phenprocoumon in 61,205 AF patients. Hazard ratios (HRs) for effectiveness and...
Source: Thrombosis and Haemostasis - January 22, 2018 Category: Hematology Authors: Hohnloser SH, Basic E, Hohmann C, Nabauer M Tags: Thromb Haemost Source Type: research

The Clinical Significance of Fibrin Monomers.
CONCLUSION:  Utilizing FM concentrations to assess hyper-coagulable patients seems promising; however, there are limitations including variations in FM cut-off values, the effect of patient medications and the timing of FM measurement relative to an acute event. Thus, further investigation is required before a true advantage for FM as a haemostatic marker can be established. PMID: 30312978 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 12, 2018 Category: Hematology Authors: Refaai MA, Riley P, Mardovina T, Bell PD Tags: Thromb Haemost Source Type: research

Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study.
CONCLUSION:  In the first study of a nationwide population cohort, we show that compliance with the simple ABC pathway is associated with improved clinically relevant outcomes of patients with AF. Given the high health care burden associated with AF, such a streamlined holistic approach to AF management should be implemented, to improve the care of such patients. PMID: 31266082 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 1, 2019 Category: Hematology Authors: Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Joung B, Lip GYH Tags: Thromb Haemost Source Type: research

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
CONCLUSIONS: Persistent systemic inflammatory activity, assessed by repeated IL-6 measurements, is associated with mortality independent of established clinical risk factors and other strong cardiovascular biomarkers in anticoagulated patients with AF. PMID: 32510737 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 7, 2020 Category: Hematology Authors: Aulin J, Hijazi Z, Siegbahn A, Andersson U, Alexander JH, Connolly SJ, Ezekowitz MD, Gersh BJ, Granger CB, Horowitz J, Hylek EM, Lopes RD, Yusuf S, Wallentin L, Oldgren J Tags: J Thromb Haemost Source Type: research

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.
CONCLUSIONS: In GARFIELD-AF, despite similar characteristics, patients on anticoagulants were treated differently in NL and BE. Although the rate of major bleeding was 33% higher in NL, variations in bleeding, mortality and TE rates were not statistically significant. PMID: 32886853 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 3, 2020 Category: Hematology Authors: Seelig J, Hemels MEW, Xhaët O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman JR, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Piete Tags: J Thromb Haemost Source Type: research

Adherence to the 'Atrial Fibrillation Better Care' (ABC) Pathway in Patients with Atrial Fibrillation
CONCLUSION: Adherence to the ABC pathway was suboptimal, being adopted in 1 in every 5 patients. Adherence to the ABC pathway was associated with a reduction in the risk of major adverse outcomes.PMID:34020488 | DOI:10.1055/a-1515-9630
Source: Thrombosis and Haemostasis - May 21, 2021 Category: Hematology Authors: Giulio Francesco Romiti Daniele Pastori Jos é Miguel Rivera-Caravaca Wern Yew Ding Ying X Gue Danilo Menichelli Jakub Gumprecht Monika Koziel Pil-Sung Yang Yutao Guo Gregory Yh Lip Marco Proietti Source Type: research

Severe left atrial spontaneous echo contrast in non-valvular atrial fibrillation: Clinical characteristics and impact on ischemic risk post-ablation
Conclusions Higher BNP, ESR, LAd/∆LVED were the independent predictors for severe SEC. Severe SEC were associated with higher peri-procedural and long-term ischemic risks. ESR and LAd/∆LVED, as indicators of hematological and hemodynamic change, seemed helpful in identifying NVAF patients prone to developing severe SEC.PMID:36402133 | DOI:10.1055/a-1983-0516
Source: Thrombosis and Haemostasis - November 19, 2022 Category: Hematology Authors: Hao Wang Siqi Xi Jindong Chen Liang Zhao Tian Gan Ben He Source Type: research

Frailty and subsequent adverse outcomes in older patients with atrial fibrillation treated with oral anticoagulants: The Shizuoka study
CONCLUSION: Patients with frailty in whom OAC therapy is initiated have higher risk of bleeding, highlighting the importance of discussing this increased risk with patients with AF who have frailty and assessing frailty at the time of OAC initiation.PMID:37168397 | PMC:PMC10165150 | DOI:10.1016/j.rpth.2023.100129
Source: Thrombosis and Haemostasis - May 11, 2023 Category: Hematology Authors: Shiori Nishimura Hiraku Kumamaru Satoshi Shoji Eiji Nakatani Hiroyuki Yamamoto Nao Ichihara Alexander T Sandhu Yoshiki Miyachi Hiroaki Miyata Shun Kohsaka Source Type: research

Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry
CONCLUSION: This Win Ratio analysis demonstrates the significant benefits of NOACs over warfarin and ABC pathway adherence over nonadherence in reducing the composite outcome in patients with AF.PMID:37625457 | DOI:10.1055/s-0043-1772773
Source: Thrombosis and Haemostasis - August 25, 2023 Category: Hematology Authors: Sukrit Treewaree Gregory Y H Lip Rungroj Krittayaphong Source Type: research

Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
In conclusion, based on this modelling exercise, the utilisation of apixaban and dabigatran for thromboprophylaxis could provide a profound annual mathematical net clinical benefit on stroke and major bleeds, in European AF patients. PMID: 23179181 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 22, 2012 Category: Hematology Authors: Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY Tags: Thromb Haemost Source Type: research